{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T23:07:54Z","timestamp":1768259274442,"version":"3.49.0"},"reference-count":10,"publisher":"BMJ","issue":"10","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2020,9,28]]},"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:p>Extended half-life of factor IX (FIX) demonstrated clinical benefit and lower treatment burden than standard half-life FIX products in clinical trials. We analysed the impact in efficacy, pharmacokinetics (PKs) and costs of the switch from nonacog alfa (rFIX) to albutrepenonacog alfa (rFIX-FP) in the first patient with haemophilia B (HB) treated in Spain outside clinical trials. A 7-year-old boy presented with HB with poor venous access and repetition infections using rFIX, which was switched to rFIX-FP. Prophylaxis was adjusted by PKs using WAPPS-Hemo tailoring from 100 IU\/kg\/week of rFIX to 80 IU\/kg\/3 weeks of rFIX-FP. Comparing 6 months before, rFIX-FP reduced 68.5% FIX consumption\/kg and 58.3% infusion frequency, but total costs\/weight showed a slight increase. Ratio of half-life between rFIX and rFIX-FP was 3.4\u20133.7. This case report revealed that switch to rFIX-FP decreased frequency and FIX consumption, without adverse events and bleeds.<\/jats:p>","DOI":"10.1136\/bcr-2019-234142","type":"journal-article","created":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T17:00:15Z","timestamp":1602608415000},"page":"e234142","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical, pharmacokinetic and economic analysis of the first switch to an extended half-life factor IX (albutrepenonacog alfa, rFIX-FP) in Spain"],"prefix":"10.1136","volume":"13","author":[{"given":"Manuel","family":"Rodr\u00edguez L\u00f3pez","sequence":"first","affiliation":[{"name":"Haemostasis and Thrombosis Unit, Hospital \u00c1lvaro Cunqueiro, Vigo, Galicia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0369-5341","authenticated-orcid":false,"given":"Juan Eduardo","family":"Meg\u00edas Vericat","sequence":"additional","affiliation":[{"name":"Pharmacy Department and Haemostasis and Thrombosis Unit, Hospital Universitari i Polit\u00e8cnic La Fe, Valencia, Spain"},{"name":"Pharmacy University, Universitat de Valencia, Valencia, Comunitat Valenciana, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Albo L\u00f3pez","sequence":"additional","affiliation":[{"name":"Haemostasis and Thrombosis Unit, Hospital \u00c1lvaro Cunqueiro, Vigo, Galicia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8390-8211","authenticated-orcid":false,"given":"Santiago","family":"Bonanad","sequence":"additional","affiliation":[{"name":"Haemostasis and Thrombosis Unit, Hospital Universitari i Polit\u00e8cnic La Fe, Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,10,13]]},"reference":[{"key":"2025082801544165000_13.10.e234142.1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/2040620718802606","article-title":"Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B","volume":"9","author":"Mahlangu","year":"2018","journal-title":"Ther Adv Hematol"},{"key":"2025082801544165000_13.10.e234142.2","unstructured":"Informe de Posicionamiento Terap\u00e9utico de albutrepenonacog alfa (Idelvion\u00ae) en hemofilia B. Available: https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT-albutrepenonacog-alfa-Idelvion-hemofilia-B.pdf [Accessed 1 Oct 2019]."},{"key":"2025082801544165000_13.10.e234142.3","doi-asserted-by":"crossref","DOI":"10.2196\/resprot.6558","article-title":"Development of a Web-Accessible population pharmacokinetic Service-Hemophilia (WAPPS-Hemo): study protocol","volume":"5","author":"Iorio","year":"2016","journal-title":"JMIR Res Protoc"},{"key":"2025082801544165000_13.10.e234142.4","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/hae.13013","article-title":"The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO","volume":"22","author":"Collins","year":"2016","journal-title":"Haemophilia"},{"key":"2025082801544165000_13.10.e234142.5","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jth.13867","article-title":"Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH","volume":"15","author":"Iorio","year":"2017","journal-title":"J Thromb Haemost"},{"key":"2025082801544165000_13.10.e234142.6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-669234"},{"key":"2025082801544165000_13.10.e234142.7","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1160\/TH16-03-0179","article-title":"Long-Acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial","volume":"116","author":"Kenet","year":"2016","journal-title":"Thromb Haemost"},{"key":"2025082801544165000_13.10.e234142.8","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1160\/TH16-12-0942","article-title":"Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life fix concentrates","volume":"117","author":"Iorio","year":"2017","journal-title":"Thromb Haemost"},{"key":"2025082801544165000_13.10.e234142.9","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1111\/jth.13771","article-title":"In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients","volume":"15","author":"Preijers","year":"2017","journal-title":"J Thromb Haemost"},{"key":"2025082801544165000_13.10.e234142.10","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1111\/jth.14292","article-title":"Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery","volume":"16","author":"Preijers","year":"2018","journal-title":"J Thromb Haemost"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2019-234142","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T08:54:50Z","timestamp":1756371290000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2019-234142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":10,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10,13]]},"published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1136\/bcr-2019-234142"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2019-234142","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10]]}}}